1Marberger M J, Andersen J T, Nickel J C, etal. Prostate volume and serum prostate-specific antigen as pre- dictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials [J].Eur Urol, 2000, 38:563--568.
2Roehrborn C G, McConnell J D, Saltzman B, et al. Storage (Irritative) and Voiding (Obstructive) Symp- toms as Predictors of Benign Prostatic Hyperplasia Progression and Related Outeomes[J]. Eur Urol, 2002, 42:1--6.
3McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology [J ]. BJU Int, 2006, 97 (Suppl 2): 23-28.
4I.aumann E O, Paik A, Rosen R C. Sexual dysfunction in the United States: prevalence and predictors[J]. JA- MA, 1999, 281: 537--544.
5Braun M H, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey" [J]. Eur Urol , 2003,44, 588- 94.
6McConnell J D, Roehrborn C G, Bautista O M, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J ]. N Engl J Med, 2003, 349: 2387-2398.
7Jimenez-Cruz F. Identifying patients with lower urinary tract symptoms/ benign prostatic hyperplasia at risk for progression[J]. Eur Urol, 2003, 2: 6--12.
8Jacobsen S J, Jacobson D J, Girman C J, et al. Natural history of prostatism: risk factors for acute urinary retention[J]. J Urol, 1997, 158:481-487.
9Roehrborn C G, Malice M, Cook T J, et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH : a comprehensive analysis of the pooled placebo groups of several large clinical trials[J]. Urology, 2001, 58:210-216.
10Emberton M, Cornel E B, Bassi P F, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management [J]. Int J Clin Praet, 2008, 62: 1076-1086.
